1. The Defendant: (a) KRW 46,409,981; (b) KRW 17,403,992 to Plaintiff C; and (c) from July 6, 2011 to each of the above amounts.

1. Basic facts

A. The parties concerned are corporations that operate Tolin University Sub-Ammetric Hospital (hereinafter “Defendant Hospital”).

The deceased D (hereinafter referred to as the “the deceased”) is a person who died while being treated as hepatitis at the Defendant Hospital, and the plaintiff B is the deceased’s spouse, the plaintiff C, and the deceased’s children.

B. On August 1, 1994, the deceased was first admitted to the Defendant Hospital as a virial virus B, and had regularly undergone a function test from the medical staff of the said hospital. 2) On August 2003, the deceased confirmed that the cirrosis (Clevudine) was damaged by the cirrosis that was developed by the Defendant Hospital by the medical staff of the Defendant Hospital and caused damage to the cirrosis because the cirrosis (Clevudine) was a therapy to suppress the activities of the hirrosis for patients with chronic activity-oriented hepatitis B, which was developed by the Defendant Hospital.

Accordingly, on April 209, 2009, the Malarbs Co., Ltd., which had sold Clickidine in Korea, was also suspended from selling.

On August 22, 2003, the clinical experiment was recommended, and the Clatidine was recovered from August 22, 2003.

However, until February 5, 2004, the deceased had symptoms of diversating Crelidine on a total of nine occasions, and thereafter, the deceased voluntarily suspended the use of clothes.

3. On July 22, 2004, the Deceased was subject to the organization inspection by the medical staff of the Defendant Hospital, and there was no outcome of that inspection.

In addition to those diagnosed as chronic liver infections, the deceased was regularly admitted to the Defendant Hospital and undergone an ultra-frequency test, etc.